Type 2 diabetes raises the risk of cognitive decline and dementia, but not everyone with the disease follows the same trajectory. A narrative review published in Discover Aging argues that two molecular players—an Alzheimer’s-linked gene variant called APOE ε4 and an aging-related protein called α-Klotho—may jointly shape who stays cognitively resilient and who slips toward impairment. The authors, led by Ricardo Cardoso Cassilhas, propose a three-layered model in which metabolic, vascular/inflammatory, and neurodegenerative damage interact, with APOE ε4 amplifying injury across all three layers and α-Klotho offering a counterweight.
The scale of the underlying problem is substantial. Nearly 589 million people aged 20 to 79 live with diabetes worldwide, a figure projected to reach roughly 853 million by 2050. Type 2 diabetes accounts for about 90 percent of cases, and its prevalence is highest in older adults—the very group most vulnerable to cognitive deterioration. Two independent meta-analyses cited in the review quantified the dementia risk: Gudala and colleagues reported a 73 percent higher risk among people with type 2 diabetes compared with those without the disease, while Cao and colleagues estimated a 59 percent elevation. Older individuals with diabetes show measurable declines in attention, memory, executive function, and processing speed—domains that directly affect self-care and adherence to treatment, creating a bidirectional loop in which worsening cognition undermines diabetes management.
Mechanistically, the review describes type 2 diabetes as a state of brain insulin resistance, sometimes dubbed type 3 diabetes. Chronic hyperglycemia drives central insulin resistance, neuroinflammation mediated by NF-κB signaling, beta-amyloid deposition, and tau hyperphosphorylation—the hallmark pathologies of Alzheimer’s disease. Sustained high blood sugar also promotes the neuronal accumulation of advanced glycation end products, impairs astrocytic activity, compromises the blood–brain barrier, and reduces glucose uptake by neurons. Together, the authors write, these changes erode synaptic plasticity and diminish cognitive reserve, leaving the aging brain less able to withstand additional insults.
Against this backdrop, the APOE ε4 allele enters as a well-documented genetic risk factor. Compared with the more common ε3 variant, ε4 increases the risk of dementia and cognitive impairment, particularly in executive function, attention, and memory. In a longitudinal MRI study of older adults with type 2 diabetes, ε4 carriers showed accelerated hippocampal atrophy over three years compared with noncarriers. The review also cites evidence that ε4 carriers exhibit more pronounced cerebral amyloid angiopathy and greater blood–brain barrier fragility, potentially exacerbated in a synergistic fashion by the vascular stress imposed by diabetes and by interactions with advanced glycation end products.
Yet the epidemiological picture within diabetes populations is more complicated than the genetics alone would suggest. The review highlights studies in which ε4 status failed to predict cognitive outcomes in people with type 2 diabetes: Samaras and colleagues reported no influence of the allele on cognitive performance, and Manzali and colleagues found that the ε4 genotype did not predict cognitive decline in older diabetic individuals. The authors interpret this as evidence that the metabolic and vascular burden of diabetes may act as a dominant driver of impairment, potentially attenuating or masking the genetic susceptibility typically conferred by ε4. Adding another wrinkle, Wu and colleagues found that metformin use was associated with memory preservation only in non-ε4 carriers, hinting that the allele may also modify therapeutic response.
On the resilience side sits α-Klotho, a protein initially discovered as an aging-suppressor gene whose deficiency induces a premature-aging phenotype and whose overexpression extends lifespan by up to 30 percent in animal models. Circulating in a soluble form in plasma and cerebrospinal fluid, α-Klotho enhances insulin signaling in neural tissue by activating the PI3K/Akt pathway, lowers IRS-1 serine phosphorylation, and promotes neuronal glucose uptake. It also inhibits tau hyperphosphorylation and beta-amyloid formation, activates the antioxidant Nrf2 pathway with upregulation of enzymes such as superoxide dismutase and heme oxygenase-1, and suppresses inflammation through the NLRP3 inflammasome and inhibition of NF-κB, TNF-α, and IL-6. In type 2 diabetes, circulating α-Klotho levels tend to be reduced and correlate with chronic hyperglycemia and oxidative stress, while higher levels show a positive association with cognitive performance—one that appears more pronounced in women than in men, possibly reflecting the protein’s regulation by sex hormones such as estrogens.
Much of the strongest evidence for α-Klotho’s cognitive effects comes from preclinical work. Dubal and colleagues showed that elevated α-Klotho, achieved through transgenic overexpression and intraventricular administration in aged mice, enhanced hippocampal-dependent memory and increased NMDA receptor-dependent long-term potentiation, accompanied by higher synaptic levels of the GluN2B receptor subunit. In Morris Water Maze testing, Klotho-overexpressing mice reached the original platform location roughly 2.5 times faster than controls. Leon and colleagues achieved similar synaptic and behavioral gains in mice with a peripherally administered recombinant α-Klotho fragment, and Gupta and colleagues found that administering the KL1 domain remodeled metabolomic signatures and improved hippocampus-dependent memory in both young and aged mice. In Rhesus macaques, exogenous α-Klotho administration improved memory and neuroplasticity. These are animal findings, and the review is careful to frame them as translational leads rather than established human benefits.
The interplay between the two biomarkers forms the conceptual core of the review. Raber and colleagues reported that higher concentrations of α-Klotho in plasma and cerebrospinal fluid were associated with better cognitive performance and lower amyloid beta, independent of APOE ε4 carrier status—suggesting resilience mechanisms that operate regardless of genotype. Genetic variation adds another layer: heterozygosity for the KL-VS polymorphism is associated with higher serum α-Klotho levels and longevity, and Dubal’s team demonstrated that KL-VS heterozygosity reduces the adverse cognitive effects of APOE ε4. More recently, Chen and colleagues found that KL-VS heterozygosity in ε4 noncarriers was associated with slower cognitive decline in late-onset Alzheimer’s disease, while Shibata and colleagues, analyzing longitudinal data from the Alzheimer’s Disease Neuroimaging Initiative, found that ε4 noncarriers carrying the KL-VS variant showed the greatest preservation of cognitive function over time—especially memory—whereas ε4 carriers without the variant declined most steeply, and carriers of both variants showed an intermediate trajectory.
The authors integrate these threads into a three-layered translational model: metabolic dysregulation with hyperglycemia and insulin resistance; vascular and inflammatory injury involving endothelial dysfunction and proinflammatory cytokines; and synaptic and neurodegenerative damage marked by reduced cerebral BDNF and hippocampal atrophy. APOE ε4 amplifies each layer while α-Klotho exerts protective influence across all of them, a dynamic the authors describe as a reserve-buffering effect. From this they sketch a biomarker-informed screening panel for older adults with diabetes—APOE ε4 genotyping, serum α-Klotho measurement, executive function and memory testing, and possibly neuroimaging for white matter hyperintensities and hippocampal atrophy—consistent with the 2025 American Diabetes Association guidelines, which now include cognitive screening for elderly people with diabetes.
The review’s own limitations temper any clinical enthusiasm. Most of the human data derive from observational or cross-sectional cohorts rather than randomized or interventional studies, precluding firm causal inference and leaving room for residual confounding and reverse causality. Biomarkers are measured with heterogeneous assays and platforms, with no harmonized clinical cut-offs or standardized reference ranges, hampering comparison across studies. Few clinical trials or longitudinal cohorts have examined the simultaneous relationship between these genetic variables and cognitive trajectories in older adults with diabetes. The authors therefore present their model as hypothesis-generating: any combined APOE–Klotho screening approach should, for now, remain confined to research settings, awaiting prospective validation in adequately powered longitudinal cohorts before it can inform routine clinical decisions.
Subject of Research: The interaction of APOE ε4 and alpha-Klotho in cognitive risk and resilience in type 2 diabetes
Article Title: Cognitive risk and resilience in diabetes involving APOE ε4 and alpha klotho: a narrative review
Article References: Cassilhas, R. C., Prates, J. T. A. C., Pires, R. F., & Raber, J. (2026). Cognitive risk and resilience in diabetes involving APOE ε4 and alpha klotho: a narrative review. Discover Aging, 1(1), Article 2. https://doi.org/10.1007/s44518-026-00001-6
Image Credits: AI Generated
DOI: 10.1007/s44518-026-00001-6
Keywords: type 2 diabetes, APOE ε4, alpha-Klotho, cognitive decline, dementia, Alzheimer's disease, insulin resistance, blood-brain barrier, KL-VS polymorphism, cognitive reserve, narrative review, biomarkers
News Source: Cassandra Pierce. (October 29, 2026). Diabetes Dementia Risk Hinges on APOE ε4 and Alpha-Klotho, Review Argues. Scienmag.
